These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1102 related articles for article (PubMed ID: 9135694)
1. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Habib FK; Ross M; Tate R; Chisholm GD Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694 [TBL] [Abstract][Full Text] [Related]
2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065 [TBL] [Abstract][Full Text] [Related]
3. Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. Stanczyk FZ; Azen CG; Pike MC J Steroid Biochem Mol Biol; 2013 Nov; 138():10-6. PubMed ID: 23474436 [TBL] [Abstract][Full Text] [Related]
4. Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. Geller J J Clin Endocrinol Metab; 1990 Dec; 71(6):1552-5. PubMed ID: 1699965 [TBL] [Abstract][Full Text] [Related]
5. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710 [TBL] [Abstract][Full Text] [Related]
6. Effects of competitive and noncompetitive 5α-reductase inhibitors on serum and intra-prostatic androgens in beagle dogs. Zhao XF; Yang Y; Wang W; Qiu Z; Zhang P; Wang B Chin Med J (Engl); 2013 Feb; 126(4):711-5. PubMed ID: 23422194 [TBL] [Abstract][Full Text] [Related]
7. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia]. Bartsch G; Rittmaster RS; Klocker H Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma. Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152 [TBL] [Abstract][Full Text] [Related]
9. Changes in the Serum Prostatic Biomarkers During the Treatment of Benign Prostatic Hyperplasia with a 5alpha-reductase Inhibitor: Finasteride. Golchin-Rad K; Mogheiseh A; Nazifi S; Ahrari Khafi MS; Derakhshandeh N; Abbaszadeh-Hasiri M Top Companion Anim Med; 2020 Mar; 38():100405. PubMed ID: 32115076 [TBL] [Abstract][Full Text] [Related]
10. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content. Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302 [TBL] [Abstract][Full Text] [Related]
11. Androgen metabolism in men receiving finasteride before prostatectomy. Norman RW; Coakes KE; Wright AS; Rittmaster RS J Urol; 1993 Nov; 150(5 Pt 2):1736-9. PubMed ID: 7692110 [TBL] [Abstract][Full Text] [Related]
12. Androgen-induced prostate-specific antigen gene expression is mediated via dihydrotestosterone in LNCaP cells. Zhu YS; Cai LQ; You X; Cordero JJ; Huang Y; Imperato-McGinley J J Androl; 2003; 24(5):681-7. PubMed ID: 12954658 [TBL] [Abstract][Full Text] [Related]
13. Androgen metabolism in the prostate of the finasteride-treated, adult rat: a possible explanation for the differential action of testosterone and 5 alpha-dihydrotestosterone during development of the male urogenital tract. George FW Endocrinology; 1997 Mar; 138(3):871-7. PubMed ID: 9048585 [TBL] [Abstract][Full Text] [Related]
14. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291 [TBL] [Abstract][Full Text] [Related]
15. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression. Cohen SM; Werrmann JG; Rasmusson GH; Tanaka WK; Malatesta PF; Prahalada S; Jacobs JG; Harris G; Nett TM Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of 5alpha-reductase in rat prostate reveals differential regulation of androgen-response gene expression by testosterone and dihydrotestosterone. Dadras SS; Cai X; Abasolo I; Wang Z Gene Expr; 2001; 9(4-5):183-94. PubMed ID: 11444528 [TBL] [Abstract][Full Text] [Related]
17. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia. Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955 [TBL] [Abstract][Full Text] [Related]
18. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804 [TBL] [Abstract][Full Text] [Related]
19. Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride. Geller J; Sionit L J Cell Biochem Suppl; 1992; 16H():109-12. PubMed ID: 1283893 [TBL] [Abstract][Full Text] [Related]
20. Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia. Park BK; Kim CW; Kwon JE; Negi M; Koo YT; Lee SH; Baek DH; Noh YH; Kang SC Pharm Biol; 2019 Dec; 57(1):90-98. PubMed ID: 30724641 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]